A Phase II Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma.

Trial Profile

A Phase II Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 in Subjects With Persistent Mild to Moderate Asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2013

At a glance

  • Drugs TC 6987 (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Mar 2012 Primary endpoint 'Forced-expiratory-volume-in-1-second' has been met, according to a Targacept media release.
    • 27 Mar 2012 Status changed from active, no longer recruiting to completed, according to a Targacept media release.
    • 21 Feb 2012 Topline results are expected in the first half of 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top